Rallybio (RLYB)
(Delayed Data from NSDQ)
$1.10 USD
0.00 (0.00%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $1.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.10 USD
0.00 (0.00%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $1.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Zacks News
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Rallybio (RLYB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
by Zacks Equity Research
RallyBio (RLYB) gains 83% after announcing a collaboration deal with J&J to develop novel therapies to reduce the risk of FNAIT in pregnant women, along with funding of $6.6 million from the latter.
Wall Street Analysts Believe Rallybio Corporation (RLYB) Could Rally 202.36%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Rallybio Corporation (RLYB) points to a 202.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Rallybio Corporation (RLYB) Have the Potential to Rally 290.63% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 290.6% upside potential for Rallybio Corporation (RLYB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Down -19.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Rallybio Corporation (RLYB)
by Zacks Equity Research
Rallybio Corporation (RLYB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie
by Zacks Equity Research
AbCellera (ABCL) inks a strategic collaboration with AbbVie to develop new antibody therapies across multiple indications. ABCL shares rise.
Rallybio (RLYB) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Rallybio (RLYB) has been struggling lately, but the selling pressure may be coming to an end soon.
Rallybio (RLYB) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Rallybio (RLYB) has been struggling lately, but the selling pressure may be coming to an end soon.